Global Nuclear Medicine Radiopharmaceuticals Market Strategic Research Report
By Type: Diagnostic Imaging Radiopharmaceuticals (SPECT/PET), Therapeutic Radiopharmaceuticals (Theranostics), Isotope Production & Precursor Supply
By Application: Oncology, Cardiology, Neurology, Other Clinical Applications
Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America
Key Players: Novartis/AAA, Curium Pharma, Lantheus Holdings, GE HealthCare, Bayer, Eckert & Ziegler, Telix Pharmaceuticals, Fusion Pharmaceuticals
Vista general
Nuclear medicine radiopharmaceuticals are diagnostic and therapeutic agents incorporating radioactive isotopes (technetium-99m, fluorine-18, lutetium-177, iodine-131, gallium-68, and others) used in imaging (PET, SPECT) and targeted radionuclide therapy for oncology, cardiology, and neurology applications. The market spans diagnostic imaging tracers -- the largest established segment, dominated by technetium-99m-based bone and cardiac perfusion scans and increasingly PET tracers like FDG and PSMA-targeted agents -- and the rapidly expanding therapeutic radiopharmaceutical (theranostics) segment, exemplified by Novartis's Pluvicto and Lutathera, which has redefined the category's growth trajectory.
Growth is driven overwhelmingly by the therapeutic radiopharmaceutical segment's rapid clinical and commercial expansion following Pluvicto and Lutathera's success in prostate cancer and neuroendocrine tumors respectively, which has triggered a wave of pharmaceutical company investment, M&A, and pipeline development in targeted radionuclide therapy across additional cancer types. A secondary driver is continued PET imaging infrastructure expansion globally supporting growth in the diagnostic tracer segment, particularly PSMA PET imaging which has become standard-of-care in prostate cancer staging. The primary restraint is the specialized, time-sensitive supply chain radiopharmaceuticals require (many isotopes have half-lives measured in hours, necessitating localized production and rapid distribution networks), which constrains market access in regions lacking cyclotron or reactor infrastructure, alongside capacity bottlenecks in isotope production (particularly lutetium-177 and actinium-225) that limit therapeutic radiopharmaceutical scale-up.
This report covers the global nuclear medicine radiopharmaceuticals market by isotope/modality type, clinical application, and region, along with competitive profiles of leading radiopharmaceutical companies. It is intended for oncology and nuclear medicine clinical teams, radiopharmaceutical industry investors and M&A advisors, and nuclear medicine supply chain and isotope production planners.
Market snapshot
Global Nuclear Medicine Radiopharmaceuticals Market Strategic Research Report snapshot, 2025–2032
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.Segments covered in this report
Table of contents
01Executive Summary
- 1.1 Market Synopsis
- 1.2 Key Findings
- 1.3 Strategic Recommendations
02Industry Overview & Forecast
- 2.1 Market Definition & Scope
- 2.2 Market Value Forecast, 2025-2032
- 2.3 CAGR Analysis & Confidence Intervals
- 2.4 Historical Market Review, 2019-2024
- 2.5 Scenario Analysis (Base, Bull, Bear Cases)
03Market Segmentation by Type
- 3.1 Market by Type Overview
- 3.2 Diagnostic Imaging Radiopharmaceuticals (SPECT/PET) (Value)
- 3.3 Therapeutic Radiopharmaceuticals (Theranostics) (Value)
- 3.4 Isotope Production & Precursor Supply (Value)
04Market Segmentation by Application
- 4.1 Market by Application Overview
- 4.2 Oncology (Value)
- 4.3 Cardiology (Value)
- 4.4 Neurology (Value)
- 4.5 Other Clinical Applications (Value)
05Regional Market Forecast
- 5.1 Regional Revenue Share & CAGR (2024 vs 2032)
- 5.2 North America (Value)
- 5.3 Europe (Value)
- 5.4 Asia Pacific (Value)
- 5.5 Rest of World
06Country-Level Market Forecast
- 6.1 Top Countries Overview
- 6.2 United States
- 6.3 Germany
- 6.4 Japan
- 6.5 France
- 6.6 China
07Growth Drivers & Inhibitors
- 7.1 Therapeutic Radiopharmaceutical (Theranostics) Commercial Success
- 7.2 PSMA PET Imaging Standard-of-Care Adoption
- 7.3 Pharmaceutical Company M&A and Pipeline Investment
- 7.4 Market Restraints & Challenges
- 7.5 Opportunities & White-Space Analysis
08Key Company Profiles
- 8.1 Novartis (Advanced Accelerator Applications) — Revenue, Strategy, Key Products
- 8.2 Curium Pharma — Revenue, Strategy, Key Products
- 8.3 Lantheus Holdings — Revenue, Strategy, Key Products
- 8.4 GE HealthCare — Revenue, Strategy, Key Products
- 8.5 Bayer AG (Radiopharmaceuticals) — Revenue, Strategy, Key Products
- 8.6 Eckert & Ziegler — Revenue, Strategy, Key Products
- 8.7 Telix Pharmaceuticals — Revenue, Strategy, Key Products
- 8.8 Fusion Pharmaceuticals (AstraZeneca) — Revenue, Strategy, Key Products
09Competitive Landscape
- 9.1 Market Concentration & Competitive Intensity
- 9.2 Market Share Analysis (2024)
- 9.3 Competitive Positioning Matrix
- 9.4 Recent Developments: M&A, Partnerships & Product Launches (2023-2025)
10Porter's Five Forces Analysis
- 10.1 Threat of New Entrants
- 10.2 Bargaining Power of Buyers
- 10.3 Bargaining Power of Suppliers
- 10.4 Threat of Substitute Products
- 10.5 Competitive Rivalry Intensity
11PESTLE Analysis
- 11.1 Political Factors
- 11.2 Economic Factors
- 11.3 Social & Demographic Factors
- 11.4 Technological Factors
- 11.5 Legal & Regulatory Factors
- 11.6 Environmental Factors
12SWOT Analysis
- 12.1 Market-Level Strengths
- 12.2 Market-Level Weaknesses
- 12.3 Strategic Opportunities
- 12.4 External Threats
13Future Trends & Outlook
- 13.1 Expansion of Targeted Alpha Therapy Pipeline
- 13.2 Isotope Production Capacity Investment
- 13.3 Pharmaceutical Company Vertical Integration into Radiopharma
- 13.4 Long-Term Market Outlook (2033-2035)
- 13.5 Investment & M&A Activity Outlook
Frequently asked questions
What is the size of the nuclear medicine radiopharmaceuticals market?
What is the CAGR of the nuclear medicine radiopharmaceuticals market?
What is driving growth in the nuclear medicine radiopharmaceuticals market?
Who are the leading companies in the nuclear medicine radiopharmaceuticals market?
Which region dominates the nuclear medicine radiopharmaceuticals market?
What segments are covered in this report?
What is the forecast period covered in this report?
Research Methodology
All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.
Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.
Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.
Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.
CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.
All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.
On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.
Related reports
Navadhi Market Research · PharmaceuticalsGlobal Peptide Market Strategic Intelligence Suite
The Global Peptide Market Strategic Intelligence Suite 2026–2031 is Navadhi Market Research's most comprehensive intelligence offering on the global peptide industry…
Navadhi Market Research · PharmaceuticalsGlobal Oncology Market Strategic Research Report
The global oncology market is undergoing a historic structural transformation driven by three simultaneous pharmaceutical supercycles - the immunotherapy/checkpoint …
Navadhi Market Research · PharmaceuticalsGlobal Peptide Therapy Market Strategic Research Report
The global peptide therapy market is undergoing an unprecedented structural transformation driven by the GLP-1 revolution - the extraordinary commercial success of G…
Need a customized version?
Get country-, segment- or company-specific intelligence tailored to your exact requirements.
Request custom research →Request a free sample
Receive a sample of Global Nuclear Medicine Radiopharmaceuticals Market Strategic Research Report before you buy.
Customize This Report
Describe your specific requirements and our analysts will scope and deliver a tailored version.
Request Invoice
We will email a proforma invoice within 24 hours. Report access is granted upon payment confirmation.
Leading Brands in This Industry
